Henry Schein (HSIC)
NASDAQ:HSIC
Want to see HSIC full AI Analyst Report?
Top Page
Henry Schein
(NASDAQ:HSIC)
Select Model
Select Model
Rating:60Neutral
Price Target:
$77.00
▼(-2.32% Downside)
Action:Reiterated
Date:05/22/26
HSIC scores as a steady but not pristine setup: financial fundamentals are held back by sustained margin compression, higher leverage, and softer recent free cash flow, despite improving sales momentum. The latest earnings call is a meaningful positive due to reiterated guidance and strong non-GAAP operational performance plus a defined cost-improvement plan. Technical indicators are mixed with limited momentum, and valuation appears moderate based on the provided P/E.
Positive Factors
Recurring consumables distribution
Henry Schein's core distribution of consumables produces repeat ordering and sticky customer relationships, creating durable, predictable revenue and inventory turnover. That recurring demand supports steady top-line visibility, stable working capital cycles and long-term cash generation for the business.
Negative Factors
Elevated leverage
Material debt accumulation reduces financial flexibility and increases interest and refinancing risk. Higher leverage constrains the company's ability to fund M&A, invest in growth, or absorb shocks, making multi‑quarter execution and realization of cost savings more critical to restore balance‑sheet headroom.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables distribution
Henry Schein's core distribution of consumables produces repeat ordering and sticky customer relationships, creating durable, predictable revenue and inventory turnover. That recurring demand supports steady top-line visibility, stable working capital cycles and long-term cash generation for the business.
Read all positive factors
Henry Schein Key Performance Indicators (KPIs)
Henry Schein (HSIC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.10B
Dividend YieldN/A
Average Volume (3M)1.28M
Price to Earnings (P/E)23.3
Beta (1Y)0.33
Revenue Growth5.64%
EPS Growth2.92%
CountryUS
Employees25,000
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)3.34
Shares Outstanding113,916,756
10 Day Avg. Volume1,389,561
30 Day Avg. Volume1,278,409
Financial Highlights & Ratios
PEG Ratio3.22
Price to Book (P/B)2.83
Price to Sales (P/S)0.70
P/FCF Ratio16.05
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue0.95
Enterprise Value/Gross Profit3.20
Enterprise Value/Ebitda12.70
Forecast
1Y Price Target
$87.50Price Target Upside11.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)5.35
Revenue Forecast (FY)$13.75B
Henry Schein Business Overview & Revenue Model
Company Description
Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices,...
How the Company Makes Money
Henry Schein makes money primarily by selling and distributing healthcare products and related services to dental and medical practices and other care settings. Its core revenue model is product distribution: it purchases branded and proprietary c...
Henry Schein Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call presented multiple strong operational and financial positives — solid revenue growth (+6.3% total, 2.5% internal), non-GAAP margin expansion (+28 bps), adjusted EBITDA growth (+11.6%), cloud/customer momentum (+25% cloud subscribers), rapid e-commerce adoption (80%+ U.S. dental e-commerce), and an explicit multi-year value-creation plan with a $125 million 2026 run-rate target and a >$200 million longer-term target. Offsetting these were manageable but important risks: a Q1 GAAP margin dip and slight GAAP net income decline, negative Q1 operating cash flow (seasonal), softness in medical diagnostics due to a light flu season, digital equipment ASP pressure, restructuring costs ($12M in Q1), and exposure to rising oil/freight costs. Overall, the positives (growth, margin expansion on a non-GAAP basis, technology and e-commerce traction, and clear cost-transformation initiatives) materially outweigh the near-term headwinds and execution costs, supporting an optimistic outlook grounded with prudent caveats around macro and timing of savings.Positive Updates
Top-line Sales Growth
Global sales of $3.4 billion, up 6.3% year-over-year (2.5% internal/local currency, 3.1% favorable foreign exchange, 0.7% acquisitions).
Negative Updates
GAAP Profitability & EPS Nuances
GAAP operating margin was 5.41%, down 12 basis points year-over-year; GAAP net income declined to $107 million (Q1 2026) from $110 million (Q1 2025).
Read all updates
Q1-2026 Updates
Positive
Negative
Top-line Sales Growth
Global sales of $3.4 billion, up 6.3% year-over-year (2.5% internal/local currency, 3.1% favorable foreign exchange, 0.7% acquisitions).
Read all positive updates
Company Guidance
Management reiterated unchanged 2026 non‑GAAP guidance calling for total sales growth of approximately 3%–5% versus 2025, non‑GAAP diluted EPS of $5.23–$5.37 (assuming an ~24% non‑GAAP tax rate), and adjusted EBITDA to grow in the mid‑single‑digits versus 2025 adjusted EBITDA of $1.1 billion; they did not provide GAAP guidance because restructuring costs remain under evaluation and guidance excludes restructuring and related items. Guidance assumptions include stable dental and medical end markets, foreign exchange roughly consistent with current levels, and the ability to mitigate tariff and higher oil‑price effects, with value‑creation benefits weighted to the back half of 2026; management reiterated an operating‑income improvement goal of >$200 million annual (with a $125 million run‑rate by end‑2026) and said remeasurement gains in 2026 are expected to be less than 2025. Management noted Q1 results that support the outlook: global sales $3.4B (+6.3% YoY), adjusted EBITDA $289M (+11.6% YoY), and first‑quarter non‑GAAP EPS $1.32.Henry Schein Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
54
Neutral
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.38B | 13.18B | 12.67B | 12.34B | 12.65B | 12.40B |
| Gross Profit | 3.97B | 3.84B | 3.77B | 3.65B | 3.65B | 3.67B |
| EBITDA | 1.00B | 1.01B | 941.00M | 877.00M | 977.00M | 1.07B |
| Net Income | 395.00M | 398.00M | 390.00M | 416.00M | 538.00M | 623.91M |
Balance Sheet | ||||||
| Total Assets | 11.30B | 11.21B | 10.22B | 10.57B | 8.61B | 8.48B |
| Cash, Cash Equivalents and Short-Term Investments | 138.00M | 156.00M | 122.00M | 171.00M | 117.00M | 118.00M |
| Total Debt | 3.75B | 3.69B | 2.87B | 2.74B | 1.50B | 1.22B |
| Total Liabilities | 6.48B | 6.42B | 5.38B | 5.42B | 3.94B | 3.81B |
| Stockholders Equity | 3.27B | 3.25B | 3.39B | 3.65B | 3.45B | 3.42B |
Cash Flow | ||||||
| Free Cash Flow | 431.00M | 573.00M | 661.00M | 313.00M | 506.00M | 630.57M |
| Operating Cash Flow | 578.00M | 712.00M | 848.00M | 500.00M | 602.00M | 709.58M |
| Investing Cash Flow | -368.00M | -477.00M | -430.00M | -1.14B | -276.00M | -677.22M |
| Financing Cash Flow | -153.00M | -111.00M | -510.00M | 701.00M | -315.00M | -332.96M |
Henry Schein Technical Analysis
Positive
78.83
Price Trends
75.80
Positive
76.28
Positive
73.66
Positive
Market Momentum
1.71
Negative
62.65
Neutral
66.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HSIC, the sentiment is Positive. The current price of 78.83 is above the 20-day moving average (MA) of 77.63, above the 50-day MA of 75.80, and above the 200-day MA of 73.66, indicating a bullish trend. The MACD of 1.71 indicates Negative momentum. The RSI at 62.65 is Neutral, neither overbought nor oversold. The STOCH value of 66.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HSIC.
Henry Schein Risk Analysis
Henry Schein disclosed 29 risk factors in its most recent earnings report. Henry Schein reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Henry Schein Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $2.23B | 11.71 | 10.29% | ― | -4.31% | -8.94% | |
66 Neutral | $87.88B | 19.25 | -265.44% | 0.37% | 12.36% | 48.80% | |
63 Neutral | $51.94B | 33.43 | -55.72% | 0.98% | 12.80% | 2.04% | |
62 Neutral | $54.76B | 21.15 | 115.93% | 0.66% | 5.95% | 51.04% | |
60 Neutral | $9.10B | 23.26 | 11.86% | ― | 5.64% | 2.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HSIC
Henry Schein
79.92
7.94
11.03%
COR
Cencora
271.83
-22.70
-7.71%
CAH
Cardinal Health
221.77
58.22
35.59%
MCK
McKesson
750.63
24.67
3.40%
PBH
Prestige Consumer Healthcare
46.97
-36.47
-43.71%
Henry Schein Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Henry Schein Names New Independent Chairman Amid Governance Shift
Positive
May 22, 2026
At Henry Schein’s 2026 annual meeting of stockholders on May 21, 2026, investors re-elected all ten incumbent directors to terms expiring in 2027, approved on an advisory basis the company’s 2025 executive compensation program, and rat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.